DRL gears up for biosimilar push, consumer health growth post record FY25

May 20, 2025

Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by analysts.

More To Explore

Hexaware Technologies Q2 Results: Profit jumps 38% YoY to Rs 380 crore but misses estimates

Hexaware Technologies posted a 38% YoY profit rise to ₹380 crore in Q2, but missed expectations due to higher costs and muted revenue. Revenue guidance

July 25, 2025

Sobha Ltd Q1 profit jumps over 2-fold to Rs 13.61 cr, revenue rises to Rs 901 cr

Realty firm Sobha Ltd on Friday reported a more than two times increase in its consolidated net profit to Rs 13.61 crore for the quarter

July 25, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003